Business Description
Zimmer Biomet Holdings Inc
NAICS : 339113
SIC : 3842
345 East Main Street, Warsaw, IN, USA, 46580
Compare
Compare
Traded in other countries / regions
ZBH.Austria
•
Z1BH34.Brazil
•
ZIM.Germany
•
ZBH.Mexico
•
ZBH.Switzerland
•
0QQD.UK
•
ZBH.USA
Description
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | 3.92 | |||||
| Interest Coverage | 5.58 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.73 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.5 | |||||
| 3-Year EBITDA Growth Rate | 15.7 | |||||
| 3-Year FCF Growth Rate | -7 | |||||
| 3-Year Book Growth Rate | 3.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 4.77 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -2.48 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.06 | |||||
| 9-Day RSI | 67.38 | |||||
| 14-Day RSI | 65.07 | |||||
| 6-1 Month Momentum % | 0.16 | |||||
| 12-1 Month Momentum % | -14.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.81 | |||||
| Quick Ratio | 0.95 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 378.92 | |||||
| Days Sales Outstanding | 66.56 | |||||
| Days Payable | 54.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.78 | |||||
| Dividend Payout Ratio | 0.7 | |||||
| Forward Dividend Yield % | 0.83 | |||||
| 5-Year Yield-on-Cost % | 0.78 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.57 | |||||
| Operating Margin % | 13.54 | |||||
| Net Margin % | 3.1 | |||||
| ROE % | 1.85 | |||||
| ROA % | 1 | |||||
| ROIC % | 4.12 | |||||
| ROC (Joel Greenblatt) % | 11.49 | |||||
| ROCE % | 2.52 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 106.53 | |||||
| Forward PE Ratio | 17.86 | |||||
| PE Ratio without NRI | 76.9 | |||||
| Shiller PE Ratio | 35.47 | |||||
| Price-to-Owner-Earnings | 21.05 | |||||
| PS Ratio | 3.3 | |||||
| PB Ratio | 2.01 | |||||
| Price-to-Free-Cash-Flow | 20.67 | |||||
| Price-to-Operating-Cash-Flow | 17.59 | |||||
| EV-to-EBIT | 59.56 | |||||
| EV-to-Forward-EBIT | 23.68 | |||||
| EV-to-EBITDA | 19.21 | |||||
| EV-to-Forward-EBITDA | 15.05 | |||||
| EV-to-Revenue | 4.07 | |||||
| EV-to-Forward-Revenue | 4.41 | |||||
| EV-to-FCF | 25.51 | |||||
| Price-to-Projected-FCF | 1.09 | |||||
| Price-to-Median-PS-Value | 0.99 | |||||
| Earnings Yield (Greenblatt) % | 1.68 | |||||
| Forward Rate of Return (Yacktman) % | 2.42 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6,634.71 | ||
| EPS (TTM) (€) | 0.988 | ||
| Beta | 0 | ||
| Volatility % | 21.97 | ||
| 14-Day RSI | 65.07 | ||
| 14-Day ATR (€) | 1.540491 | ||
| 20-Day SMA (€) | 109.943 | ||
| 12-1 Month Momentum % | -14.21 | ||
| 52-Week Range (€) | 93.549779 - 125.91001 | ||
| Shares Outstanding (Mil) | 209.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zimmer Biomet Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||